Although Canada is home to some of the world’s leading clinical trialists, the country falls short of the level of efficiency and streamlined processes other nations have created for clinical trials. This gap was exemplified when the COVID-19 pandemic hit, and other countries broke ground, in record speed, with vaccines and treatments. Clinical trialists in Canada had to ask themselves why we did not.

In early 2023, the Canadian Institutes of Health Research committed $39 million over three years to the newly created national consortium, Accelerating Clinical Trials (ACT) / d’Accélérer les essais cliniques (AEC) to facilitate the conduct, implementation, and results translation from high-quality, high-impact randomized controlled trials (RCTs) to improve health in Canada and around the world.

This pan-Canadian consortium brings together hundreds of researchers from 28 networks, 11 trial units, patient-partners, the biotechnology industry, government, and experts in research ethics review processes, contracts, insurance, regulatory processes, patient engagement, clinical trials training, communications, and knowledge mobilization – from Nova Scotia to British Columbia and Nunavut.

The 1st annual meeting of the ACT Canada consortium was held April 17-18, 2023 in Hamilton, Ontario. (Full agenda – PDF.)

Video: Accelerating Clinical Trials (ACT) / d’Accélérer les essais cliniques (AEC)

Back To Top